Emerging bispecific antibodies (e.g., cadonilimab) and novel agents targeting T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) (e.g., Tiragolumab, MK-7684), lymphocyte activation gene-3(LAG-3) (e.g., IMP321, BMS-986016, LAG525), and T cell immunoglobulin and mucin domain containing-3 (TIM-3) (e.g., TSR-022, MBG453) are under clinical evaluation to overcome resistance in advanced NSCLC [22]. Here, LAG3 is linked to non-small cell lung carcinoma.